Clinical trial
An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®) for the Prevention of Stroke in Patients With Atrial Fibrillation (AF), Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and the Prevention of Recurrent DVT and PE in the Secondary Care Hospital Setting in England and Wales.
NCT01871194 is registered in ClinicalTrials.gov with Professor Saad Shakir as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®) for the Prevention of Stroke in Patients With Atrial Fibrillation (AF), Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and the Prevention of Recurrent DVT and PE in the Secondary Care Hospital Setting in England and Wales.
- Lead sponsor
- Professor Saad Shakir
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 31, 2013
- Completion date
- September 30, 2017
- Enrollment
- 3,400 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
atrial fibrillation, deep vein thrombosis, pulmonary embolism